• MeSH
• Administration, Oral MeSH
• Diabetes Mellitus, Type 2 drug therapy   complications   MeSH
• Sodium-Glucose Transporter 2 Inhibitors MeSH
• Risk Assessment MeSH
• Hypoglycemic Agents administration & dosage   adverse effects   MeSH
• Dipeptidyl-Peptidase IV Inhibitors administration & dosage   pharmacology   adverse effects   MeSH
• Cardiovascular System drug effects   MeSH
• Humans MeSH
• Liraglutide administration & dosage   pharmacology   adverse effects   MeSH
• Numbers Needed To Treat MeSH
• Glucagon-Like Peptide-1 Receptor agonists   administration & dosage   MeSH
• Sitagliptin Phosphate administration & dosage   pharmacology   adverse effects   MeSH
• Sodium-Glucose Transporter 2 administration & dosage   pharmacology   MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Publication type
• Clinical Study MeSH
• Clinical Trial MeSH

• MeSH
• Diabetes Mellitus, Type 2 * drug therapy   MeSH
• Drug Combinations MeSH
• Glycated Hemoglobin analysis   drug effects   metabolism   MeSH
• Hypoglycemic Agents * therapeutic use   MeSH
• Insulin Glargine * therapeutic use   administration & dosage   MeSH
• Blood Glucose drug effects   metabolism   MeSH
• Middle Aged MeSH
• Humans MeSH
• Peptides * therapeutic use   administration & dosage   MeSH
• Glucagon-Like Peptide-2 Receptor MeSH
• Aged MeSH
• Treatment Outcome MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Letter MeSH

AIM: To evaluate the effectiveness and safety in routine clinical practice of insulin glargine/lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D) according to age. METHODS: Patient-level data were pooled from 1316 adults with T2D inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi for 24 weeks. Participants were classified into age subgroups of younger than 65 years (N = 806) and 65 years or older (N = 510). RESULTS: Compared with participants aged younger than 65 years, those aged 65 years or older had a numerically lower mean body mass index (31.6 vs. 32.6 kg/m2 ), a longer median diabetes duration (11.0 vs. 8.0 years), were more likely to receive prior basal insulin (48.4% vs. 43.5%) and had a lower mean HbA1c (8.93% [74.10 mmol/mol] vs. 9.22% [77.28 mmol/mol]). Similar and clinically relevant reductions in HbA1c and fasting plasma glucose from baseline to week 24 of iGlarLixi therapy were observed regardless of age. At 24 weeks, least-squares adjusted mean (95% confidence interval [CI]) change in HbA1c from baseline was -1.55% (-1.65% to -1.44%) in those aged 65 years or older and -1.42% (-1.50% to -1.33%) in those aged younger than 65 years (95% CI: -0.26% to 0.00%; P = .058 between subgroups). Low incidences of gastrointestinal adverse events and hypoglycaemic episodes were reported in both age subgroups. iGlarLixi decreased mean body weight from baseline to week 24 in both subgroups (-1.6 kg in those aged ≥ 65 years and -2.0 kg in those aged < 65 years). CONCLUSIONS: iGlarLixi is effective and well tolerated in both younger and older people with uncontrolled T2D.

• MeSH
• Diabetes Mellitus, Type 2 * complications   drug therapy   MeSH
• Adult MeSH
• Drug Combinations MeSH
• Glycated Hemoglobin MeSH
• Hypoglycemic Agents adverse effects   MeSH
• Insulin Glargine adverse effects   MeSH
• Blood Glucose MeSH
• Humans MeSH
• Prospective Studies MeSH
• Aged MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Aged MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

INTRODUCTION: iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) has demonstrated glycaemic efficacy and safety in adults with inadequately controlled type 2 diabetes mellitus (T2DM). Per the European Medicines Agency's product label, iGlarLixi should be injected once a day within 1 h prior to a meal, preferably the same meal every day when the most convenient meal has been chosen. It is however unknown whether iGlarLixi administration timing affects glycaemic control and safety, as clinical trial evidence is mainly based on pre-breakfast iGlarLixi administration. Therefore, we assessed the effectiveness and safety of iGlarLixi in clinical practice, according to its administration timing. METHODS: Data were pooled from two prospective observational studies including 1303 European participants with T2DM inadequately controlled on oral antidiabetic drugs with or without basal insulin who initiated iGlarLixi therapy for 24 weeks. Participants were classified into four subgroups based on daily timing of iGlarLixi injection: pre-breakfast (N = 436), pre-lunch (N = 262), pre-dinner (N = 399), and those who switched iGlarLixi injection time during the study (N = 206). RESULTS: No meaningful differences in baseline characteristics were observed between the study groups. Least-squares mean reductions in haemoglobin A1c (HbA1c) from baseline to week 24 were substantial in all groups, with the numerically largest decrease observed in the pre-breakfast group (1.57%) compared with the pre-lunch (1.27%), pre-dinner (1.42%), or changed injection time (1.33%) groups. Pre-breakfast iGlarLixi injection also resulted in a numerically greater proportion of participants achieving HbA1c < 7.0% at week 24 (33.7% versus 19.0% for pre-lunch, 25.6% pre-dinner, and 23.2% changed injection time). iGlarLixi was well tolerated across all groups, with low rates of gastrointestinal disorders and hypoglycaemia. Mean body weight decreased similarly in all groups (by 1.3-2.3 kg). CONCLUSION: iGlarLixi was effective and safe regardless of its daily administration time. However, pre-breakfast iGlarLixi injection resulted in a more effective glycaemic control.

• Publication type
• Journal Article MeSH

• MeSH
• Diabetes Mellitus, Type 2 * drug therapy   MeSH
• Insulin, Long-Acting administration & dosage   therapeutic use   MeSH
• Glucagon-Like Peptide 1 analogs & derivatives   administration & dosage   therapeutic use   MeSH
• Glycated Hemoglobin analysis   metabolism   MeSH
• Hypoglycemic Agents * administration & dosage   therapeutic use   MeSH
• Insulin Detemir administration & dosage   therapeutic use   MeSH
• Drug Therapy, Combination MeSH
• Blood Glucose analysis   metabolism   MeSH
• Humans MeSH
• Liraglutide administration & dosage   therapeutic use   MeSH
• Metformin therapeutic use   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH
• Randomized Controlled Trial MeSH

• MeSH
• Bariatric Surgery * adverse effects   MeSH
• Diabetes Mellitus, Type 2 * complications   surgery   MeSH
• Duodenum surgery   MeSH
• Cardiovascular Diseases * surgery   MeSH
• Humans MeSH
• Obesity, Morbid * complications   surgery   MeSH
• Obesity complications   surgery   MeSH
• Risk Factors MeSH
• Treatment Outcome MeSH
• Gastric Bypass * adverse effects   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH